title: Effects of LIF dose and laminin plus fibronectin on axotomized sciatic nerves.
abstract: Leukemia inhibitory factor (LIF), a cytokine which has neurotrophic and myotrophic activities, has been shown to enhance nerve regeneration and consequent return of muscle function in the entubulation model of sciatic nerve repair. Fibronectin (FN) and laminin (LN) are two extracellular matrix (ECM) components that, when combined, promote axon growth in the entubulation model. The aim of this study was to determine the optimal LIF dose and the efficacy of FN plus LN administered either alone or simultaneously with the optimal LIF dose. We found that at 12 weeks following nerve repair, a single 10 ng LIF dose produced the largest medial gastrocnemius (MG) muscle mass (P < 0.0001) and maximum force contraction (P < 0.001). The diameter of the axons in the FN plus LN group were significantly greater than for saline (P < 0.001) and the LIF dose groups (P < 0.01). When 10 ng LIF was combined with FN plus LN, the MG muscle mass was significantly greater than the optimal LIF dose (P < 0.05), suggesting an additive effect. Our findings support the view that combinations of factors, which perhaps act on complementary mechanisms for nerve regeneration, will be required to maximally potentiate nerve regeneration and return of muscle function after nerve injury.
authors.affiliation: Bernard O'Brien Institute of Microsurgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia. dowsinbj@svhm.org.au
authors.forename: B J
authors.initials: BJ
authors.lastname: Dowsing
authors.forename: A
authors.initials: A
authors.lastname: Hayes
authors.forename: T M
authors.initials: TM
authors.lastname: Bennett
authors.forename: W A
authors.initials: WA
authors.lastname: Morrison
authors.forename: A
authors.initials: A
authors.lastname: Messina
mesh_terms: D000818:Animals; D001369:Axons / Q000648:ultrastructure; D019771:Axotomy; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005353:Fibronectins / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D015850:Interleukin-6; D007797:Laminin / Q000494:pharmacology*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000502:physiology; D009413:Nerve Fibers, Myelinated / Q000648:ultrastructure; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000033:anatomy & histology / Q000187:drug effects*
chemical_list: D004338:Drug Combinations; D005353:Fibronectins; D006131:Growth Inhibitors; D015850:Interleukin-6; D007797:Laminin; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines